- Home
- UBS vs BMY Comparison
UBS vs BMY Comparison
Compare UBS & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBS | BMY |
|---|---|---|
| Founded | 1862 | 1887 |
| Country | Switzerland | United States |
| Employees | N/A | 32500 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.9B | 123.7B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | UBS | BMY |
|---|---|---|
| Price | $43.87 | $58.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $60.30 | ★ $62.13 |
| AVG Volume (30 Days) | 2.5M | ★ 9.1M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | 1.26% | ★ 4.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.68 | N/A |
| Revenue Next Year | $2.97 | N/A |
| P/E Ratio | ★ $17.22 | $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.08 | $42.52 |
| 52 Week High | $49.36 | $62.89 |
Technical Indicators
Market Signals| Indicator | UBS | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 69.77 | 49.63 |
| Support Level | $36.48 | $56.45 |
| Resistance Level | $48.90 | $62.39 |
| Average True Range (ATR) | 0.74 | 1.31 |
| MACD | 0.56 | 0.04 |
| Stochastic Oscillator | 90.67 | 35.54 |
Price Performance
Historical ComparisonAbout UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.